In8Bio, Inc. Stock Price, News & Analysis

IN8bio, Inc. (Nasdaq: INAB) announced a promising update on INB-200, the first genetically modified gamma-delta T cell therapy in clinical trials for glioblastoma multiforme (GBM). Currently in a Phase 1 trial, Cohort 1 has completed dosing with no dose limiting toxicities or serious adverse events, while Cohort 2 is actively enrolling patients. Notably, all treated patients exceeded expected progression-free survival intervals, demonstrating a potential improvement in overall survival. The trial aims to assess safety, tolerability, and efficacy of the therapy combined with standard chemotherapy.

IN8bio has announced encouraging early results from its ongoing Phase 1 trial of INB-100, a gamma-delta T cell therapy for patients with acute myeloid leukemia (AML). Three patients have received treatment, all of whom remain in remission, with two achieving durable responses lasting over 1.5 years. The therapy demonstrated a manageable safety profile, with no significant adverse events reported. This trial aims to explore the efficacy of this novel treatment for patients undergoing haploidentical stem cell transplants, where relapse rates can be high.

IN8bio, Inc. (Nasdaq: INAB) has announced the promotion of Kate Rochlin, Ph.D., to Chief Operating Officer, effective immediately. Dr. Rochlin, who has been with IN8bio since August 2020, previously served as Vice President, Operations and Innovation. She will oversee multiple operational functions and will continue to lead early innovation programs. The company is advancing its gamma-delta T cell therapies aimed at treating solid and liquid tumors, utilizing its proprietary DeltEx platform. IN8bio is conducting two Phase 1 clinical trials for its lead product candidates.

IN8bio, Inc. has appointed Trishna Goswami, M.D. as Chief Medical Officer, effective immediately. Dr. Goswami brings over a decade of experience in immuno-oncology drug development, having worked with notable companies such as Gilead and AstraZeneca. Her expertise includes clinical development for both solid and hematologic tumors, making her a significant addition to IN8bio's leadership team. The company focuses on advancing gamma-delta T cell therapies using its DeltEx platform to improve cancer treatment outcomes. This appointment aligns with IN8bio's goal of progressing multiple therapeutic candidates through clinical development.

IN8bio (Nasdaq: INAB) announced a poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 13, 2021. Dr. Kate Rochlin will present preclinical data on the potential of DeltEx drug-resistant immunotherapy gamma-delta T cells combined with PARP inhibitors to enhance tumor immunogenicity. Notably, temozolomide and niraparib resulted in up to a 29-fold increase in NKG2DL expression in resistant glioblastoma cell lines. This indicates the potential of orthogonal therapies to improve clinical efficacy against solid tumors.

IN8bio, Inc. (Nasdaq: INAB) raised $32.3 million in net proceeds from its IPO, enhancing its capital for clinical programs. The company completed patient dosing of INB-100 in a Phase 1 trial for leukemia while also publishing preclinical data on INB-200 in Scientific Reports. Financial results for Q3 2021 show a cash position of $40.7 million, with R&D expenses rising to $1.4 million. Net loss for the quarter was $3.4 million, compared to $1.7 million in Q3 2020. IN8bio continues to expect initial trial results in 2022 and topline results for all cohorts in 2023.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced its participation in three scientific conferences this November. Presentations will cover gammas-delta T-cell therapies aimed at treating various cancers. Key events include the Protein & Antibody Engineering Summit on November 4, the SITC Annual Meeting on November 13, and the Society for Neuro-Oncology meeting on November 19. Presenters include top executives and scientists from IN8bio, showcasing innovative cancer treatment approaches using the DeltEx platform.

IN8bio announced significant survival benefits from concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) in high-grade glioma models. The findings, published in Scientific Reports, support the clinical development of the company’s Drug Resistant Immunotherapy (DRI) technology. Currently, a Phase 1 trial is evaluating DRI with TMZ in glioblastoma multiforme at the University of Alabama at Birmingham. This approach aims to enhance tumor response while maintaining immune functionality.

IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will present at BioFuture 2021 on October 5 at 10:30 a.m. EDT and participate in a panel on oncology at 1:30 p.m. EDT. Additionally, Kate Rochlin, VP of Operations, will present on gamma-delta T-cell programs at the Advanced Therapies Congress & Expo 2021 the same day at 11:30 a.m. EDT. IN8bio focuses on innovative therapies for tumors using its DeltEx platform, with two Phase 1 trials ongoing for gamma-delta T-cell products targeting glioblastoma and leukemia.